TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
26 hedge funds and large institutions have $12.6M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
18% more funds holding
Funds holding: 22 → 26 (+4)
2.37% less ownership
Funds ownership: 33.91% → 31.55% (-2.4%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
64% less capital inflows, than outflows
Capital inflows: $719K | Capital outflows: $1.97M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James & Associates
St Petersburg,
Florida
|
+$211K |
| 2 |
Renaissance Technologies
New York
|
+$145K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$104K |
| 4 |
Bank of New York Mellon
New York
|
+$90.9K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$76.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.27M |
| 2 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$536K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$122K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$27.4K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$8.54K |
TCON Hedge Fund Activity: Q2 2017 in Review
26 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2017, worth a combined $12.6M — down 40% from $21.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TCON positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Raymond James & Associates, opening a new position worth an estimated $211K. The largest seller was Franklin Resources, cutting an estimated $1.27M.
- 26 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2017, up from 22 in Q1 2017.
- Funds reported $12.6M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2017, down 40% quarter-over-quarter.
- 5 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2017 and 1 closed out, a net change of +4 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2017 was Raymond James & Associates, an estimated $211K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2017 was Franklin Resources, an estimated $1.27M sold.
Based on aggregated 13F filings for Q2 2017.